2020.04.22
No opposition filed against NBHL’s European patent for anti-CCR7 antibodies
We are informed by European Patent Office that on expiry of the opposition period no notice of opposition has been filed against the NBHL’s European patent for anti-CCR7 antibodies granted in 2019.
Title of the invention: Anti-human CCR7 antibodies, hybridoma, medical composition, and antibody-immobilized carrier
Patent number: EP 2 623 592
Application number: 11829086.5
Proprietor: NB Health Laboratory Co. Ltd.
CCR7 is a GPCR involved in the pathogenesis of fibrosis and cancer. We will continue to proceed with the development of therapeutic anti-CCR7 antibodies.